Jimi Choi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jimi Choi has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
- Dong-Hyuk Cho
Division of Cardiology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
13 shared publications - Byung-Su Yoo
Division of Cardiology, Department of Internal Medicine, Yonsei University, Wonju College of Medicine, Wonju, Korea
10 shared publications - Sin Gon Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Korea
10 shared publications - Jong-Chan Youn
Division of Cardiology, Department of Internal Medicine, Seoul St. Mary’s Hospital, Catholic Research Institute for Intractable Cardiovascular Disease, College of Medicine, The Catholic University of Korea, Seoul, Korea
7 shared publications - Kyeong Jin Kim
Division of Endocrinology and Metabolism, Department of Internal Medicine, Korea University Anam Hospital, Seoul, Korea
7 shared publications - Chan Joo Lee
Division of Cardiology, Department of Internal Medicine, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea
6 shared publications
Latest Publications
- Open Access
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Association of Poor Adherence to Guideline-Directed Medical Treatment With Adverse Events Including Fatal Arrhythmia in Heart Failure With Reduced Ejection Fraction: A Nationwide Cohort Analysis
Kim M, et al. Korean Circ J. 2027 ;57:e48. https://doi.org/10.4070/kcj.2026.0021
- 1 January 2027
- Published by XMLink in Korean Circulation Journal
- Vol. 57
Open AccessAssociation of Poor Adherence to Guideline-Directed Medical Treatment With Adverse Events Including Fatal Arrhythmia in Heart Failure With Reduced Ejection Fraction: A Nationwide Cohort Analysis
Kim M, et al. Korean Circ J. 2027 ;57:e48. https://doi.org/10.4070/kcj.2026.0021
- Open Access
- 28 September 2026
- Published by Wiley in Journal of Diabetes Investigation
Metabolic health, independent of body mass index, is associated with mortality risk in type 1 diabetes
Aims/Introduction: Although a low body mass index (BMI) is traditionally associated with high mortality in type 1 diabetes (T1D), the increasing prevalence of obesity and its association with mortality warrant further research. Materials and Methods: Using a nationwide Korean database from 2002 to 2018, we classified patients with T1D into six categories based on metabolic health and BMI (≥25, 18.5–25, and 2 ): metabolically healthy obesity (MHO), metabolically unhealthy obesity (MUO), metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy underweight (MHUW), and metabolically unhealthy underweight (MUUW). Mortality data were collected until 2020. Results: Among 8,838 patients with T1D (mean age 54.7 years, 60.6% male), the prevalence of MUUW, MHUW, MUNW, MHNW, MHO, and MUO was 1.1%, 3.0%, 28.5%, 31.2%, 6.3%, and 29.9%, respectively. Over a median 8.3‐year follow‐up, patients with MHO exhibited the lowest all‐cause mortality risk (adjusted hazard ratio [aHR], 0.70; P = 0.007), and those with MUO also had a lower risk (aHR, 0.77; P < 0.001) compared with the MHNW group. Conversely, the underweight groups had significantly higher all‐cause (MHUW: aHR, 2.08; MUUW: aHR, 3.94) and cardiovascular disease (CVD)‐related mortalities (MHUW: aHR, 2.47; MUUW: aHR, 6.31). Patients with MHO had a lower risk of CVD (aHR, 0.76), whereas those with MUO, MUNW, and MUUW had increased risks (aHRs, 1.18, 1.32, and 2.22). Conclusions: Metabolic unhealthiness was associated with a higher CVD risk, and the risks of mortality and CVD were particularly high in patients with MUUW, underscoring the importance of maintaining metabolic health in T1D.
- 28 September 2026
- Published by Wiley in Journal of Diabetes Investigation
Open AccessMetabolic health, independent of body mass index, is associated with mortality risk in type 1 diabetes
Aims/Introduction: Although a low body mass index (BMI) is traditionally associated with high mortality in type 1 diabetes (T1D), the increasing prevalence of obesity and its association with mortality warrant further research. Materials and Methods: Using a nationwide Korean database from 2002 to 2018, we classified patients with T1D into six categories based on metabolic health and BMI (≥25, 18.5–25, and 2 ): metabolically healthy obesity (MHO), metabolically unhealthy obesity (MUO), metabolically healthy normal weight (MHNW), metabolically unhealthy normal weight (MUNW), metabolically healthy underweight (MHUW), and metabolically unhealthy underweight (MUUW). Mortality data were collected until 2020. Results: Among 8,838 patients with T1D (mean age 54.7 years, 60.6% male), the prevalence of MUUW, MHUW, MUNW, MHNW, MHO, and MUO was 1.1%, 3.0%, 28.5%, 31.2%, 6.3%, and 29.9%, respectively. Over a median 8.3‐year follow‐up, patients with MHO exhibited the lowest all‐cause mortality risk (adjusted hazard ratio [aHR], 0.70; P = 0.007), and those with MUO also had a lower risk (aHR, 0.77; P < 0.001) compared with the MHNW group. Conversely, the underweight groups had significantly higher all‐cause (MHUW: aHR, 2.08; MUUW: aHR, 3.94) and cardiovascular disease (CVD)‐related mortalities (MHUW: aHR, 2.47; MUUW: aHR, 6.31). Patients with MHO had a lower risk of CVD (aHR, 0.76), whereas those with MUO, MUNW, and MUUW had increased risks (aHRs, 1.18, 1.32, and 2.22). Conclusions: Metabolic unhealthiness was associated with a higher CVD risk, and the risks of mortality and CVD were particularly high in patients with MUUW, underscoring the importance of maintaining metabolic health in T1D.
- Open Access
- 15 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (7) , 535-545
Switching to angiotensin receptor–neprilysin inhibitor and reduced risk of new-onset atrial fibrillation in heart failure with reduced ejection fraction: a nationwide propensity score–matched study
Aims: We investigated whether switching from traditional renin–angiotensin system (RAS) blockade to angiotensin receptor–neprilysin inhibitor (ARNI) is associated with a lower risk of new-onset atrial fibrillation (AF) than continuing RAS blockade in patients with heart failure with reduced ejection fraction (HFrEF) without prior AF. Methods and results: Using data from the Korean National Health Insurance Service (2017–2021), we identified 39 061 patients with HFrEF without prior AF who received either ARNI (n = 12 263) or traditional RAS blockade (n = 26 798). After 1:1 propensity score matching, 9030 patients were included in each group. The primary outcome was new-onset AF within 1 year. In the propensity score–matched cohort, new-onset AF incidence was lower in the ARNI group [10.73 vs. 12.15 per 100 person-years; hazard ratio (HR) 0.89; 95% confidence interval (CI) 0.81–0.98; P = 0.021]. The composite outcome (new-onset AF, ischaemic stroke, or all-cause death) was also reduced (HR 0.85; 95% CI 0.79–0.92; P < 0.001). In competing risk analysis, ARNI was associated with a lower subdistribution hazard of new-onset AF (sHR 0.73; 95% CI 0.58–0.91; P = 0.005). In the unmatched cohort, the HR was 0.85 (95% CI 0.75–0.96) in an exploratory model including age, sex, hypertension, chronic kidney disease, prior ischaemic stroke, socioeconomic status, residential region, and beta-blocker use, and 0.94 (95% CI 0.87–1.02) after adjustment for all measured baseline covariates. Conclusion: In this large nationwide cohort of AF-naive patients with HFrEF, switching to ARNI was associated with a lower risk of short-term new-onset AF than continuing traditional RAS blockade. As this was a retrospective study, further prospective studies are needed to confirm these findings.
- 15 September 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Cardiovascular Pharmacotherapy
- Vol. 12 (7) , 535-545
Open AccessSwitching to angiotensin receptor–neprilysin inhibitor and reduced risk of new-onset atrial fibrillation in heart failure with reduced ejection fraction: a nationwide propensity score–matched study
Aims: We investigated whether switching from traditional renin–angiotensin system (RAS) blockade to angiotensin receptor–neprilysin inhibitor (ARNI) is associated with a lower risk of new-onset atrial fibrillation (AF) than continuing RAS blockade in patients with heart failure with reduced ejection fraction (HFrEF) without prior AF. Methods and results: Using data from the Korean National Health Insurance Service (2017–2021), we identified 39 061 patients with HFrEF without prior AF who received either ARNI (n = 12 263) or traditional RAS blockade (n = 26 798). After 1:1 propensity score matching, 9030 patients were included in each group. The primary outcome was new-onset AF within 1 year. In the propensity score–matched cohort, new-onset AF incidence was lower in the ARNI group [10.73 vs. 12.15 per 100 person-years; hazard ratio (HR) 0.89; 95% confidence interval (CI) 0.81–0.98; P = 0.021]. The composite outcome (new-onset AF, ischaemic stroke, or all-cause death) was also reduced (HR 0.85; 95% CI 0.79–0.92; P < 0.001). In competing risk analysis, ARNI was associated with a lower subdistribution hazard of new-onset AF (sHR 0.73; 95% CI 0.58–0.91; P = 0.005). In the unmatched cohort, the HR was 0.85 (95% CI 0.75–0.96) in an exploratory model including age, sex, hypertension, chronic kidney disease, prior ischaemic stroke, socioeconomic status, residential region, and beta-blocker use, and 0.94 (95% CI 0.87–1.02) after adjustment for all measured baseline covariates. Conclusion: In this large nationwide cohort of AF-naive patients with HFrEF, switching to ARNI was associated with a lower risk of short-term new-onset AF than continuing traditional RAS blockade. As this was a retrospective study, further prospective studies are needed to confirm these findings.
- Open Access
- 10 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Decision tree prediction of saline infusion test outcomes in suspected primary aldosteronism: a multicenter common data model study
Context: Confirmatory aldosterone suppression testing is widely utilized following positive screening for primary aldosteronism (PA), yet its incremental diagnostic value remains debated. While the 2025 Endocrine Society guideline proposes a probability-based approach, validated tools to translate this concept into clinical decision-making, particularly in Asian populations, are lacking. Methods: Using a multicenter common data model across 3 tertiary hospitals (2002-2020), we retrospectively identified 307 patients who underwent saline infusion test (SIT) for suspected PA. Saline infusion test positivity was defined as postinfusion plasma aldosterone concentration (PAC) ≥ 10 ng/dL. We developed a conditional inference classification tree using screening-stage variables and compared its performance with conventional rigid screening criteria based on PAC and the aldosterone-to-renin ratio. Results: Among 307 patients (mean age 51.2 years), 153 (49.8%) were SIT positive. Saline infusion test-positive patients had higher PAC (median 32.9 vs 12.7 ng/dL, P < 0.001) and lower serum potassium levels (3.66 vs 4.02 mmol/L, P < .001). The decision tree identified a high-probability phenotype defined by PAC > 25 ng/dL and plasma renin activity ≤ 0.55 ng/mL/h, with an SIT positivity rate of 96.4%. In patients with a PAC of 15.7 to 25.0 ng/dL, potassium ≤ 3.9 mmol/L further stratified SIT positivity to 68.8%, whereas patients with PAC ≤ 15.7 ng/dL had a low positivity rate. The tree-derived criteria outperformed conventional cutoffs, with an accuracy of 0.85, a sensitivity of 0.83, and a specificity of 0.86, and performance remained robust in internal validation and sensitivity analyses. Conclusion: A screening-stage decision tree provides clinically interpretable probabilities for SIT positivity, supporting risk-stratified confirmatory testing and selective omission in high-probability patients.
- 10 August 2026
- Published by The Endocrine Society in The Journal of Clinical Endocrinology & Metabolism
Open AccessDecision tree prediction of saline infusion test outcomes in suspected primary aldosteronism: a multicenter common data model study
Context: Confirmatory aldosterone suppression testing is widely utilized following positive screening for primary aldosteronism (PA), yet its incremental diagnostic value remains debated. While the 2025 Endocrine Society guideline proposes a probability-based approach, validated tools to translate this concept into clinical decision-making, particularly in Asian populations, are lacking. Methods: Using a multicenter common data model across 3 tertiary hospitals (2002-2020), we retrospectively identified 307 patients who underwent saline infusion test (SIT) for suspected PA. Saline infusion test positivity was defined as postinfusion plasma aldosterone concentration (PAC) ≥ 10 ng/dL. We developed a conditional inference classification tree using screening-stage variables and compared its performance with conventional rigid screening criteria based on PAC and the aldosterone-to-renin ratio. Results: Among 307 patients (mean age 51.2 years), 153 (49.8%) were SIT positive. Saline infusion test-positive patients had higher PAC (median 32.9 vs 12.7 ng/dL, P < 0.001) and lower serum potassium levels (3.66 vs 4.02 mmol/L, P < .001). The decision tree identified a high-probability phenotype defined by PAC > 25 ng/dL and plasma renin activity ≤ 0.55 ng/mL/h, with an SIT positivity rate of 96.4%. In patients with a PAC of 15.7 to 25.0 ng/dL, potassium ≤ 3.9 mmol/L further stratified SIT positivity to 68.8%, whereas patients with PAC ≤ 15.7 ng/dL had a low positivity rate. The tree-derived criteria outperformed conventional cutoffs, with an accuracy of 0.85, a sensitivity of 0.83, and a specificity of 0.86, and performance remained robust in internal validation and sensitivity analyses. Conclusion: A screening-stage decision tree provides clinically interpretable probabilities for SIT positivity, supporting risk-stratified confirmatory testing and selective omission in high-probability patients.
- Open Access
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e044747
Effectiveness of an Intervention to Improve Guideline‐Directed Medications for Patients With Acute Heart Failure: A Randomized Clinical Trial
Background: Guideline‐directed medical therapy during the transitional period is crucial for improving outcomes in heart failure with reduced ejection fraction. We investigated whether a simplified transitional care intervention could increase guideline‐directed medical therapy adherence in patients with acute heart failure (HF). Methods: This multicenter, open‐label randomized trial enrolled 982 patients with acute HF. The transitional care intervention included a discharge checklist, HF education, and telephone monitoring. The primary outcome was achievement of high guideline adherence indicator, defined as the prescription of all 3 guideline‐directed medical therapy drugs (renin‐angiotensin system blockades, beta blockers, and mineralocorticoid receptor antagonists) at 6 months. Both modified intention‐to‐treat and per‐intervention analyses were conducted to evaluate the effectiveness of intervention components. Results: Among 982 participants (mean age, 62.4±15.5 years; 64.5% male), there was no statistical difference in the proportion achieving a high guideline adherence indicator between the intervention and control groups (49.6% versus 44.6%; OR, 1.12; 95% CI, 0.86–1.45; P =0.37). No significant differences were observed in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score or clinical outcomes. In the per‐intervention analysis, patients who received all components showed significantly higher guideline adherence indicator achievement compared with those who received no components (adjusted odds ratio [OR], 1.56 [95% CI, 1.07–2.27], P =0.02). Conclusions: In this randomized trial of patients with acute HF, although the simplified transitional care intervention did not increase high guideline adherence indicator achievement, implementation of all intervention components was associated with improved guideline adherence. Our findings emphasize that implementation fidelity is the key challenge in optimizing transitional care for HF management. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04900584.
- 19 May 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (10) , e044747
Open AccessEffectiveness of an Intervention to Improve Guideline‐Directed Medications for Patients With Acute Heart Failure: A Randomized Clinical Trial
Background: Guideline‐directed medical therapy during the transitional period is crucial for improving outcomes in heart failure with reduced ejection fraction. We investigated whether a simplified transitional care intervention could increase guideline‐directed medical therapy adherence in patients with acute heart failure (HF). Methods: This multicenter, open‐label randomized trial enrolled 982 patients with acute HF. The transitional care intervention included a discharge checklist, HF education, and telephone monitoring. The primary outcome was achievement of high guideline adherence indicator, defined as the prescription of all 3 guideline‐directed medical therapy drugs (renin‐angiotensin system blockades, beta blockers, and mineralocorticoid receptor antagonists) at 6 months. Both modified intention‐to‐treat and per‐intervention analyses were conducted to evaluate the effectiveness of intervention components. Results: Among 982 participants (mean age, 62.4±15.5 years; 64.5% male), there was no statistical difference in the proportion achieving a high guideline adherence indicator between the intervention and control groups (49.6% versus 44.6%; OR, 1.12; 95% CI, 0.86–1.45; P =0.37). No significant differences were observed in the Kansas City Cardiomyopathy Questionnaire Clinical Summary Score or clinical outcomes. In the per‐intervention analysis, patients who received all components showed significantly higher guideline adherence indicator achievement compared with those who received no components (adjusted odds ratio [OR], 1.56 [95% CI, 1.07–2.27], P =0.02). Conclusions: In this randomized trial of patients with acute HF, although the simplified transitional care intervention did not increase high guideline adherence indicator achievement, implementation of all intervention components was associated with improved guideline adherence. Our findings emphasize that implementation fidelity is the key challenge in optimizing transitional care for HF management. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT04900584.
- 13 February 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (12) , 2307-2309
Differential associations of physical activity with cardiovascular outcomes according to socioeconomic status: a nationwide cohort study of 231 156 adults
- 13 February 2026
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 33 (12) , 2307-2309
Differential associations of physical activity with cardiovascular outcomes according to socioeconomic status: a nationwide cohort study of 231 156 adults
- Open Access
Association of poor adherence to guideline-directed medical treatment with adverse events including fatal arrhythmia in heart failure with reduced ejection fraction: A nationwide cohort analysis
Background: Poor adherence to guideline-directed medical therapy (GDMT) in patients with heart failure (HF) with reduced ejection fraction is associated with higher mortality and hospitalization. However, its association with malignant arrhythmias and aborted sudden cardiac death (SCD) remains unclear. This study assessed the association between GDMT adherence and these outcomes in patients with an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D). Methods: Patients who had an ICD or CRT-D implanted for primary prevention were included. Those with sustained ventricular tachycardia (VT), ventricular fibrillation/flutter (VF/VFL), or an aborted SCD device before implantation were excluded. Adherence to renin-angiotensin system blockers (RASBs), beta blockers (BBs), and mineralocorticoid receptor antagonists (MRAs) was assessed and categorized as optimal, suboptimal, or poor. The primary outcome was a composite of all-cause mortality, sustained VT, VF/VFL, and aborted SCD. Results: Among 3,780 patients, the prescription rates were 87.5% for RASBs, 89.7% for BBs, and 74.2% for MRAs. Compared with optimal adherence, both suboptimal and poor adherence were associated with an increased risk of the primary outcome. The adverse effects of poor adherence were most evident in patients with ischemic HF. Although lower adherence was correlated with more arrhythmic events, these associations were inconsistent when clinical factors were considered. Conclusions: Lower GDMT adherence was independently associated with increased mortality despite device therapy, particularly in patients with ischemic HF. Although its relationship with arrhythmic outcomes was unclear, sustained adherence remains critical, underscoring the need for targeted interventions to enhance therapeutic continuity.
Open AccessAssociation of poor adherence to guideline-directed medical treatment with adverse events including fatal arrhythmia in heart failure with reduced ejection fraction: A nationwide cohort analysis
Background: Poor adherence to guideline-directed medical therapy (GDMT) in patients with heart failure (HF) with reduced ejection fraction is associated with higher mortality and hospitalization. However, its association with malignant arrhythmias and aborted sudden cardiac death (SCD) remains unclear. This study assessed the association between GDMT adherence and these outcomes in patients with an implantable cardioverter-defibrillator (ICD) or cardiac resynchronization therapy with a defibrillator (CRT-D). Methods: Patients who had an ICD or CRT-D implanted for primary prevention were included. Those with sustained ventricular tachycardia (VT), ventricular fibrillation/flutter (VF/VFL), or an aborted SCD device before implantation were excluded. Adherence to renin-angiotensin system blockers (RASBs), beta blockers (BBs), and mineralocorticoid receptor antagonists (MRAs) was assessed and categorized as optimal, suboptimal, or poor. The primary outcome was a composite of all-cause mortality, sustained VT, VF/VFL, and aborted SCD. Results: Among 3,780 patients, the prescription rates were 87.5% for RASBs, 89.7% for BBs, and 74.2% for MRAs. Compared with optimal adherence, both suboptimal and poor adherence were associated with an increased risk of the primary outcome. The adverse effects of poor adherence were most evident in patients with ischemic HF. Although lower adherence was correlated with more arrhythmic events, these associations were inconsistent when clinical factors were considered. Conclusions: Lower GDMT adherence was independently associated with increased mortality despite device therapy, particularly in patients with ischemic HF. Although its relationship with arrhythmic outcomes was unclear, sustained adherence remains critical, underscoring the need for targeted interventions to enhance therapeutic continuity.
- 15 January 2025
- Published by BMJ in British Journal of Sports Medicine
- Vol. 59 (11) , 774-782
Longitudinal increase in physical activity and adverse cardiovascular outcomes following the diagnosis of acute coronary syndrome
Objectives Physical activity (PA) provides protective effects against cardiovascular diseases, including ischaemic heart disease. However, recommending moderate to vigorous PA (MVPA) to patients with recent acute coronary syndrome (ACS) raises concerns owing to potential risk of recurrent ACS or fatal arrhythmias. This study investigated the association between longitudinal PA changes following an ACS diagnosis and subsequent cardiovascular outcomes, including non-fatal coronary events, non-fatal stroke and cardiovascular mortality. Methods This longitudinal cohort study used Korean National Health Insurance Service data from 2010 to 2017, comprising 30 840 patients diagnosed with ACS following invasive coronary angiography or bypass surgery. Leisure-time PA was self-reported, with the frequency and intensity measured weekly. The primary endpoint was a composite of nonfatal coronary events, non-fatal stroke and cardiovascular mortality. Multivariable Cox proportional hazards regression models assessed the association between PA changes and cardiovascular outcomes. Results Among patients with ACS (mean age: 60±11 years, men: 81.3%), mean PA levels increased from 544±556 metabolic equivalent task (MET)-min/week to 594±567 MET-min/week. Over 6.7 years of median follow-up, 5639 cardiovascular events occurred. Increased PA was associated with lower cardiovascular event risk (HR 0.95, 95% CI 0.92 to 0.98). Consistent MVPA pre-ACS and post-ACS reduced cardiovascular event risk (HR 0.87, 95% CI 0.79 to 0.96) and MVPA initiation showed a modest risk reduction (HR: 0.91, MET-min/95% CI 0.82 to 1.01). Conclusions Longitudinal increases in self-reported PA, maintenance of MVPA and possibly MVPA initiation after ACS reduced the risk of cardiovascular events. Initiating or maintaining MVPA could be an important strategy in improving cardiovascular outcomes following ACS.
- 15 January 2025
- Published by BMJ in British Journal of Sports Medicine
- Vol. 59 (11) , 774-782
Longitudinal increase in physical activity and adverse cardiovascular outcomes following the diagnosis of acute coronary syndrome
Objectives Physical activity (PA) provides protective effects against cardiovascular diseases, including ischaemic heart disease. However, recommending moderate to vigorous PA (MVPA) to patients with recent acute coronary syndrome (ACS) raises concerns owing to potential risk of recurrent ACS or fatal arrhythmias. This study investigated the association between longitudinal PA changes following an ACS diagnosis and subsequent cardiovascular outcomes, including non-fatal coronary events, non-fatal stroke and cardiovascular mortality. Methods This longitudinal cohort study used Korean National Health Insurance Service data from 2010 to 2017, comprising 30 840 patients diagnosed with ACS following invasive coronary angiography or bypass surgery. Leisure-time PA was self-reported, with the frequency and intensity measured weekly. The primary endpoint was a composite of nonfatal coronary events, non-fatal stroke and cardiovascular mortality. Multivariable Cox proportional hazards regression models assessed the association between PA changes and cardiovascular outcomes. Results Among patients with ACS (mean age: 60±11 years, men: 81.3%), mean PA levels increased from 544±556 metabolic equivalent task (MET)-min/week to 594±567 MET-min/week. Over 6.7 years of median follow-up, 5639 cardiovascular events occurred. Increased PA was associated with lower cardiovascular event risk (HR 0.95, 95% CI 0.92 to 0.98). Consistent MVPA pre-ACS and post-ACS reduced cardiovascular event risk (HR 0.87, 95% CI 0.79 to 0.96) and MVPA initiation showed a modest risk reduction (HR: 0.91, MET-min/95% CI 0.82 to 1.01). Conclusions Longitudinal increases in self-reported PA, maintenance of MVPA and possibly MVPA initiation after ACS reduced the risk of cardiovascular events. Initiating or maintaining MVPA could be an important strategy in improving cardiovascular outcomes following ACS.
- Open Access
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (10) , 907-920
Real-World Cost-Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure With Reduced Ejection Fraction in Korea
Oh BC, et al. Korean Circ J. 2025 May;55:e90. https://doi.org/10.4070/kcj.2024.0403
- 1 January 2025
- Published by XMLink in Korean Circulation Journal
- Vol. 55 (10) , 907-920
Open AccessReal-World Cost-Effectiveness of Angiotensin Receptor-Neprilysin Inhibitor in Heart Failure With Reduced Ejection Fraction in Korea
Oh BC, et al. Korean Circ J. 2025 May;55:e90. https://doi.org/10.4070/kcj.2024.0403